Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug takes on semaglutide in major trial

NCT ID NCT07668414

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 2 times

Summary

This Phase 3 trial will test whether a new drug called zenagamtide helps people with obesity lose more weight than the current treatment semaglutide. About 650 adults will receive weekly injections of either zenagamtide, semaglutide, or a placebo. The main goal is to see how much body weight changes over the study period.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zenagamtide
What this could lead to
If it works, this could offer a new weekly injection for weight loss that may be more effective or have fewer side effects than current options.
What could go wrong
This is a Phase 3 trial, but results are not yet known. The drug may not prove better than semaglutide, and side effects like nausea or other issues could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 650 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. Exclusion Criteria: * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    43 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Amarillo Med Spec LLP

    Amarillo, Texas, 79124, United States

  • Amicis Centers of Clinical Research

    St Louis, Missouri, 63128, United States

  • Artemis Insitute for Clin Res

    San Diego, California, 92123, United States

  • Chicago Research Center, Inc

    Chicago, Illinois, 60634, United States

  • Conquest Research

    Atlanta, Georgia, 30328, United States

  • Desert Oasis Healthcare

    Palm Springs, California, 92262, United States

  • Eastside Bariatric and Gen Surg

    Snellville, Georgia, 30078, United States

  • Encore Medical Research LLC

    Hollywood, Florida, 33024, United States

  • Encore Medical Research of Weston

    Weston, Florida, 33331, United States

  • Endeavor Health

    Skokie, Illinois, 60077, United States

  • Epic Medical Research

    DeSoto, Texas, 75115, United States

  • Essence MD Research

    Naples, Florida, 34102, United States

  • First Valley Medical Group

    Lancaster, California, 93534, United States

  • Florida Inst For Clin Res LLC

    Orlando, Florida, 32825, United States

  • Gastroent Consult of SW VA

    Roanoke, Virginia, 24014, United States

  • Geisinger Clinic

    Danville, Pennsylvania, 17822, United States

  • Hillcrest Clinical Research

    Simpsonville, South Carolina, 29681-1538, United States

  • Houston Research Institute

    Houston, Texas, 77079, United States

  • Ichor Research

    Syracuse, New York, 13210, United States

  • Jacksonville Ctr Clin Res

    Jacksonville, Florida, 32216, United States

  • Lillestol Research LLC

    Fargo, North Dakota, 58104, United States

  • Med Home Development Grp

    Washington D.C., District of Columbia, 20037, United States

  • Medical University Of South Carolina

    Charleston, South Carolina, 29425, United States

  • Midwest Inst For Clin Res

    Indianapolis, Indiana, 46260, United States

  • National Clin Res Inc.

    Richmond, Virginia, 23294, United States

  • NextPhase Research

    Hollywood, Florida, 33024, United States

  • Olympus Clinical Research

    Sugar Land, Texas, 77478, United States

  • Osvaldo A. Brusco MD

    Corpus Christi, Texas, 78414, United States

  • Oviedo Medical Research, LLC

    Oviedo, Florida, 32765, United States

  • Palm Beach Research Center

    West Palm Beach, Florida, 33409, United States

  • PharmaDev Clinical Research Institute LLC

    Miami, Florida, 33176, United States

  • Pinnacle Clinical Research

    Brownsville, Texas, 78520, United States

  • Rainier Clin Res Ctr Inc

    Renton, Washington, 98057, United States

  • Seattle Clinical Research Center

    Seattle, Washington, 98104, United States

  • Sleep Therapy Research Center

    San Antonio, Texas, 78229, United States

  • South Broward Research LLC

    Miramar, Florida, 33027, United States

  • Southern Clin Research

    Zachary, Louisiana, 70791, United States

  • Southgate Medical Group, LLP

    West Seneca, New York, 14224, United States

  • Spartanburg Medical Research

    Spartanburg, South Carolina, 29303, United States

  • Texas Diabetes & Endocrinology

    Austin, Texas, 78749, United States

  • The Endocrine Center

    Houston, Texas, 77079, United States

  • UT Southwestern Med Center

    Dallas, Texas, 75390, United States

  • Western University of Health Sciences

    Pomona, California, 91766, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.